Zelicapavir shows 6.7-day symptom resolution improvement in high-risk RSV adults

ENANTA PHARMACEUTICALS INC

6.7-day faster complete resolution of all 13 RSV symptoms in HR3 population (COPD/CHF/age≥75); 7.2-day improvement in total RiiQ.
Hospitalization rate 1.7% for zelicapavir vs 5.0% placebo; 2-day faster PGI-S improvement (p<0.05).
Robust antiviral effect: 4–5 day faster undetectable viral load; 23.5% vs 10.0% undetectable at end of treatment (p=0.0198).
Favorable safety: no treatment discontinuations; most common AEs diarrhea (3.3%) and asthma (2.5%).
Primary endpoint (time to mild LRTD symptoms) not met; data inform Phase 3 design and registrational endpoints.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.